Showing 1031-1040 of 20877 results for "".
- C1q Inhibitor Tanruprubart Shows Functional Benefit in Guillain-Barré Syndromehttps://reachmd.com/news/c1q-inhibitor-tanruprubart-shows-functional-benefit-in-guillain-barre-syndrome/2487601/KEY TAKEAWAYS Tanruprubart improved functional recovery in Guillain-Barré syndrome, meeting the primary end point of a phase 3 trial. Earlier treatment after symptom onset and lower baseline neurofilament light
- ONWARDS 10: Switching to Weekly Insulin Icodec Without A Loading Dosehttps://reachmd.com/news/onwards-10-switching-to-weekly-insulin-icodec-without-a-loading-dose/2487566/Key Takeaways Once-weekly icodec without an initial additional dose was associated with non-inferior HbA1c change versus daily glargine U100 at 26 weeks. Greater time in range was reported with icodec, and self-measured blood glucose did not rise after
- Inhaled GH001 for Treatment-Resistant Depressionhttps://reachmd.com/news/inhaled-gh001-for-treatment-resistant-depression/2487559/Key Takeaways Day 8 improvement in MADRS scores favored GH001 over placebo. Remission and response at day 8 were observed more often with GH001 than with placebo. Adverse events were more common with GH001, while severe or serious adverse even
- Higher Intraoperative Blood Pressure Targets Do Not Improve Outcomeshttps://reachmd.com/news/higher-intraoperative-blood-pressure-targets-do-not-improve-outcomes/2487567/Key Takeaways Higher intraoperative blood pressure targets were not associated with broader improvement in major postoperative outcomes during elective noncardiac surgery. No reduction was observed for acute kidney injury or acute myocardial injury, an
- Kidney Protection Strategy Adherence in Critically Ill Adults with AKIhttps://reachmd.com/news/kidney-protection-strategy-adherence-critical-aki/2487549/Key Takeaways Complete bundle adherence was reported in 31% of patients. Sustained MAP optimization had the lowest component-level implementation rate at 33%. Adherence was associated with a lower incidence of AKD beyond day 7, a higher incide
- Skin of Color Still Underrepresented Across Major Dermatology Image Searcheshttps://reachmd.com/news/skin-of-color-still-underrepresented-across-major-dermatology-image-searches/2487573/Skin of Color (SOC) remains significantly underrepresented in image search results across major search engines, according to a recent Letter to the Editor published in the Journal of Drugs in Dermatology. Investigators building on earlier research in the area evaluated the first 5
- Takeda Reports Positive Phase 3 Results for Oral TYK2 Inhibitor Zasocitinibhttps://reachmd.com/news/takeda-reports-positive-phase-3-results-for-oral-tyk2-inhibitor-zasocitinib/2487546/Takeda announced positive topline results from the Phase 3 LATITUDE Atlas (TAK-279-PsO-3004) trial, a head-to-head study evaluating the investigational oral tyrosine kinase 2 (TYK2) inhibitor zasocitinib (TAK-279) against deucravacitinib in adults with moderate-to-severe plaque psoriasis.
- Global Integral Beauty Conference Marks Fifth Anniversary With Expanded International Programhttps://reachmd.com/news/global-integral-beauty-conference-marks-fifth-anniversary-with-expanded-international-program/2487545/Global Integral Beauty (GIB) has announced that its 5th Global Integral Beauty Conference will be held on October 17, 2026, at the New York Marriott Marquis in New York, New York. Now entering its fifth year, the conference s
- Hugel Highlights Global Expansion and K-Aesthetics Leadership at Inaugural AMWC KOREAhttps://reachmd.com/news/hugel-highlights-global-expansion-and-k-aesthetics-leadership-at-inaugural-amwc-korea/2487542/Hugel, Inc. showcased its expanding global presence in medical aesthetics at the inaugural Aesthetic & Anti-aging Medicine World Congress Korea (AMWC KOREA), held June 19-20 in Seoul, South Korea. The meeting brought together approximately 2,000 healthcare professionals and industry leaders f
- AbbVie to Acquire Apogee Therapeutics in $10.9 Billion Immunology Dealhttps://reachmd.com/news/abbvie-to-acquire-apogee-therapeutics-in-109-billion-immunology-deal/2487547/AbbVie announced a definitive agreement to acquire Apogee Therapeutics in an all-cash transaction valued at approximately $10.9 billion, a move the manufacturer said adds to its immunology pipeline and strengthens its presence in inflammatory diseases such as atopi